The combination of computational design, laboratory-based screening and biophysical validation enables the de novo generation of variable heavy-chain antibody fragments and antibodies that precisely target chosen disease-related molecules.
- Nathaniel R. Bennett
- Joseph L. Watson
- David Baker
